Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Shield Therapeutics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 55.49.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Shield Therapeutics. This Buy consensus rating has held steady for over two years.
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.